Brief: Equillium Inc Ono Pharmaceutical Makes Strategic Business Decision To Allow Itolizumab Option To Expire
31/10/2024 11:15
Oct 31 (Reuters) - Equillium Inc EQ.O :
* EQUILLIUM INC: ONO PHARMACEUTICAL MAKES STRATEGIC BUSINESS
DECISION TO ALLOW ITOLIZUMAB OPTION TO EXPIRE
* EQUILLIUM INC: EVALUATING ACCELERATING COMPLETION OF PHASE
3
EQUATOR STUDY IN AGVHD TO Q1 2025
* EQUILLIUM INC: EQUILLIUM MAINTAINS ALL OF ITS COMMERCIAL
RIGHTS
TO ITOLIZUMAB
Source text: ID:nBw9cc5MPa
Further company coverage: EQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations